Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis

In their multicentre, double-blind, placebo-controlled phase 2b study, Emma Guttman-Yassky and colleagues showed the efficacy and safety of subcutaneous rocatinlimab versus subcutaneous placebo for the treatment of moderate-to-severe atopic dermatitis.1 Although the findings of this study are novel and encouraging, there are a few limitations that require elucidation.